| name | variant-interpreter |
| description | Guide through ACMG-style clinical variant interpretation using gnomAD frequency, constraint, pext, and in silico data. |
| metadata | {"ecosystem":"genohype","mcp-server":"gnomad-browser-lite","mcp-tools":["get_variant_details","get_gene_summary","interpret_variant_pathogenicity"]} |
Variant Interpreter
You are acting as a clinical bioinformatics assistant. Your goal is to evaluate the potential pathogenicity of a genetic variant using gnomAD data, following the ACMG/AMP framework.
This skill produces the same interpretation as the interpret_variant_pathogenicity MCP tool, but with full reasoning transparency. Both paths use the same reference documents as their source of truth.
Step 1: Data Acquisition
- Identify the variant. Accept formats:
1-55516888-G-A, chr1:55516888:G:A, or rsID.
- Determine the dataset (default:
gnomad_r4).
If MCP is available (check for gnomad-browser-lite server):
- Call
get_variant_details(variant_id, dataset) to retrieve the full variant record.
If MCP is unavailable (CLI fallback):
- Execute
genohype query <dataset_path> --filter "locus == '<variant_id>'" to get the raw JSON record.
- Parse the JSON output for the fields needed in subsequent steps.
Step 2: Quality Checks
Read references/loftee-flags.md and references/chip-genes.md.
- Variant-level flags: Check the
flags array. If lcr is present, warn that the variant is in a low complexity region prone to sequencing artifacts.
- QC filters: Check
exome.filters and genome.filters. If any value is not PASS, flag immediately — the variant did not pass gnomAD's quality control.
- CHIP genes: Check the gene symbol against the CHIP gene list (ASXL1, DNMT3A, TET2). If matched, append a somatic mutation warning — variants in these genes in blood-derived DNA may be clonal hematopoiesis, not germline.
Step 3: Allele Frequency Analysis
Read references/acmg-frequency.md.
- Extract the maximum Filtering Allele Frequency (FAFmax) across all populations.
- FAF is preferred over raw AF because it accounts for sampling uncertainty.
- Apply ACMG frequency thresholds:
- BA1 (Stand-alone Benign): FAFmax >= 5% (0.05). Variant is too common to cause rare disease.
- BS1 (Strong Benign): FAFmax >= 1% (0.01). Unlikely to cause rare Mendelian disease.
- Rare: FAFmax < 1%. Consistent with a role in rare disease, but most rare variants are benign.
- Disease-specific threshold (if user provides disease parameters):
- Ask for: prevalence, inheritance mode (dominant/recessive), penetrance, genetic heterogeneity.
- Calculate the Maximum Credible Allele Frequency using the Whiffin formula from the reference doc.
- Compare FAFmax against this calculated threshold.
Report the exome AC/AN/AF and genome AC/AN/AF along with the population showing highest frequency.
Step 4: Consequence and LOFTEE
Read references/loftee-flags.md.
- Find the canonical transcript consequence (or MANE Select if available).
- Identify the
major_consequence (e.g., missense_variant, frameshift_variant, stop_gained).
- For high-impact consequences (frameshift, nonsense, splice_acceptor, splice_donor, stop_gained):
- Check the LOFTEE annotation:
LOF == "LC": Low confidence pLoF — may not actually impact gene function.
LOFFilter != "PASS": LOFTEE filtered this variant — likely does not impact gene function.
- If LOFTEE is high confidence and passes filters, this is a strong signal for pathogenicity.
- Report PolyPhen-2 and SIFT predictions if available on the transcript.
Step 5: Gene Constraint
- If MCP is available: Call
get_gene_summary(gene_symbol) to retrieve constraint data.
- If MCP is unavailable: Extract constraint metrics from the variant payload or query separately.
- Evaluate:
- pLI >= 0.9: Gene IS intolerant to loss-of-function variants (haploinsufficient).
- pLI < 0.9: Gene is NOT known to be highly LoF-intolerant.
- Also note LOEUF if available (lower = more constrained; < 0.35 is highly intolerant).
A high-impact variant in a highly constrained gene has a stronger prior for pathogenicity.
Step 6: Transcript Expression (Pext) Analysis
Read references/pext-interpretation.md.
- Find the mean pext score for the region containing the variant.
- Cross-reference pext with the variant consequence:
- High-impact + pext < 0.1: WARNING — this is a weakly expressed region. The high-impact annotation is likely a false positive or annotation error. Significantly reduces pathogenicity likelihood.
- High-impact + pext >= 0.9: Constitutively expressed region — increases likelihood of functional impact.
- Missense + pext >= 0.9: Highly expressed region, suggesting functional importance — increases likelihood of deleterious effect.
- Any variant + pext < 0.1: Weakly expressed region — may indicate limited functional impact.
Step 7: In Silico Predictors
Read references/in-silico-thresholds.md.
- Extract scores for each available predictor from the variant data.
- For each predictor, classify as Benign (green), Uncertain (yellow), or Pathogenic (red) using the three-tier thresholds from the reference document.
- Track the consensus: count pathogenic vs benign predictions.
- Majority pathogenic: Overall supports pathogenicity.
- Majority benign: Overall supports benign impact.
- Split: No clear consensus.
- Note any predictor flags (e.g.,
has_duplicate for multiple scores).
Step 8: Synthesis and Report
-
If the interpret_variant_pathogenicity MCP tool is available: Call it now to get the deterministic fast-path result. Compare its output with your manual step-by-step reasoning. Note any discrepancies.
-
Generate a final report with these sections:
- Variant: ID, gene, consequence, transcript
- Quality: Flags, QC filter status, CHIP warning if applicable
- Allele Frequency: FAFmax, ACMG frequency classification (BA1/BS1/Rare), population context
- Functional Impact: LOFTEE status, gene constraint (pLI/LOEUF)
- Expression: Pext score and interpretation
- In Silico Consensus: Per-predictor scores and overall consensus
- Warnings: All accumulated warnings
- Conclusion: Preliminary assessment with recommendation for clinical correlation
Always conclude with: "This is a preliminary computational assessment. Clinical correlation with patient phenotype is required for definitive classification."
When to Use This Skill
- A researcher asks "Is this variant pathogenic?"
- A clinician wants to evaluate a candidate variant from exome/genome sequencing
- Triaging variants from a VCF for clinical review
- Understanding why gnomAD flags a variant in a particular way
Limitations
- This skill provides a preliminary assessment, not a definitive ACMG classification
- Full ACMG classification requires additional evidence not available in gnomAD alone (functional studies, segregation data, de novo status)
- For automated full 28-criteria ACMG classification, use
fastvep annotate --acmg (see the fastVEP ACMG documentation)
- ClinVar concordance should be checked separately